IN8bio to present at March Investor and Scientific Conferences

Rhea-AI Summary

IN8bio, Inc. (Nasdaq: INAB) announced its participation in several upcoming virtual and hybrid conferences in March 2022. Key events include the European Society for Medical Oncology Congress on March 7-8, featuring a presentation on engineered γδ T-cells, and the Cowen 42nd Annual Health Care Conference on March 7, where CEO William Ho will discuss the company overview. Additional presentations will take place at the Oppenheimer Healthcare Conference and the European Society for Blood and Marrow Transplantation meeting.

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations:

• European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress 2022 (virtual), March 7 – 8, 2022
  Kate Rochlin, Ph.D., COO
  ePoster: 23P - Engineered chemotherapy resistant γδ T-cells with combinatorial chemotherapies can enhance tumor cell immunogenicity and killing
  Visit https://bit.ly/3BTtNSI for more information

• Cowen 42^nd Annual Health Care Conference (virtual), March 7 - 9, 2022
  William Ho, CEO, will present a company overview and participate in 1x1 meetings.
  March 7, 2022, 11:10 - 11:40 a.m. EST
  Visit https://bit.ly/3Ik35oA for more information

• Oppenheimer’s 32^nd Annual Healthcare Conference (virtual), March 15 – 17, 2022
  William Ho, CEO, will present a company overview and participate in 1x1 meetings.
  March 17, 2022, 1:20 - 1:50 p.m. EDT
  Visit https://bit.ly/3IeHxd6 for more information

• 48^th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) (hybrid, Prague), March 19 – 23, 2022
  Lawrence Lamb, Ph.D., CSO
  Poster: P136 - Relapse prophylaxis post-haploidentical bone marrow transplantation and cyclophosphamide (Haplo/Cy) by infusion of donor-derived expanded/activated γδ T cells: A Phase I trial
  Visit https://bit.ly/33JVWyM for more information

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.

The proprietary IN8bio DeltEx platform is designed to overcome many of the challenges associated with the expansion, genetic engineering, and scalable manufacturing of gamma-delta T cells. The DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells. This approach allows us to expand the cells ex vivo to administer a potentially therapeutic dose to patients, harnessing the unique properties of gamma-delta T cells, including their ability to broadly recognize cellular stress signals on tumor cells. We have used the DeltEx platform to create our deep pipeline of innovative allogeneic, autologous and/or genetically modified product candidates designed to effectively target and potentially eradicate disease and improve patient outcomes.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.

For more information about IN8bio and its programs, please visit www.IN8bio.com.

Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+ 1 646.600.6438
info@IN8bio.com

Investors:
Solebury Trout
David Buck
+ 1 646.378.2927
dbuck@soleburytrout.com

Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Katie Larch
rflamm@burnsmc.com / klarch@burnsmc.com

FAQ

What conferences is IN8bio participating in March 2022?

IN8bio is participating in the European Society for Medical Oncology Congress on March 7-8, Cowen 42nd Annual Health Care Conference on March 7, Oppenheimer’s Healthcare Conference from March 15-17, and the European Society for Blood and Marrow Transplantation meeting from March 19-23.

Who will represent IN8bio at the Cowen Conference?

CEO William Ho will represent IN8bio at the Cowen 42nd Annual Health Care Conference on March 7, 2022.

What is the focus of IN8bio's research?

IN8bio focuses on developing gamma-delta T cell therapies for treating solid and liquid tumors.

What are the lead product candidates of IN8bio?

IN8bio's lead product candidates are INB-200 for glioblastoma and INB-100 for leukemia patients undergoing stem cell transplantation.

Where can I find more information about IN8bio's conferences?

More information about IN8bio's conference presentations can be found on their official website or through the links provided in the press release.

What is the significance of the DeltEx platform in IN8bio's research?

The DeltEx platform helps overcome challenges in expanding and manufacturing gamma-delta T cells, enabling the development of effective cell therapies.